anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The research examined the impact of an ethanolic extract from the leaves of Kratom (Mitragyna speciosa (Korth.) Havil.) on the growth, antioxidant capacity, immune-related gene expression, and resistance to disease caused by Edwardsiella tarda in Nile tilapia (Oreochromis niloticus). The findings revealed that the extract had the important phytochemical content in the extract included total phenolics content, total flavonoids content, vitamin C, and total antioxidant capacity and 5.42 % of the crude extract was mitragynine. The extract demonstrated antioxidant activity, as evidenced by its IC50 values against ABTS and DPPH radicals and its ferric reducing power in vitro. Moreover, the MIC-IC50 value of 0.625 mg/mL indicated that the growth of the bacteria was reduced by approximately 50 %, and the MBC was 2.50 mg/mL against E. tarda. Furthermore, the orally administered Kratom leaf extract to fingerling tilapia for 8 weeks exhibited a noticeable increase in oxidative stress, as demonstrated by the increase in MDA production in the 10 and 25 g/kg groups. It also exhibited an increase in acetylcholinesterase (AChE) activity in muscle tissue at the 50 g/kg group. However, when administered at a feeding rate of 5-10 g/kg feed, the extract showed an increase in the expression of immune-related genes (IL1, IL6, IL8, NF-kB, IFNγ, TNFα, Mx, CC-chemokine, CD4, TCRβ, MHC-IIβ, IgM, IgT, IgD) and enhanced resistance to E. tarda infection in fish. Conversely, administering the extract at 25-50 g/kg feed resulted in contrasting effects, suppressing and reducing the observed parameters. Nevertheless, feeding the extract at all concentrations for 8 weeks did not produce any changes in the histology or systemic functioning of the liver and intestines, as indicated by blood biochemistry. These findings suggest that the ethanolic leaf extract from Kratom has the potential to be used as a substitute for antibiotics in the management of bacterial infections in Nile tilapia culture, with a recommended dosage of 5-10 g/kg feed/day for a maximum of 8 weeks.
PURPOSE:To rapidly necrose.reduce malignant tumorous cells and effectively treat malignant tumors, etc., with hardly any side effects at a low cost, by heat-treating blood, blood plasma and/or serum of a living body having malignant tumors at a specific temperature and administering the resultant blood, etc., to a living body. CONSTITUTION:At least one of blood, blood plasma and serum obtained from a living body 1 having tumors is heat-treated at 37-50 deg.C temperature in a heating device 3. Immunological complexes in the above-mentioned blood (blood plasma or serum) are dissociated by the treatment to liberate malignant tumorous specific antibodies. The blood (blood plasma or serum) heat-treated in the heating device 3 is then normally cooled to a body temperature level of the living body 1 in a cooler 4, and injected into a living body 1 identical to or of the same species as that of the above-mentioned living body 1 to specifically react the above-mentioned antibodies with the malignant tumorous cells and necrose or reduce the cells. Furthermore, since the heat treatment of the blood, etc., is extracorporeally carried out, side effects are extremely rare. Since a special device is not required, this method is inexpensive.
PURPOSE: To simplify the tablet stamping method, by pushing out a medical mixture containing a polymer binding agent and forming the materials still plastic into solid type medical tablets by a table stamping machine generally used at 25 deg.C. CONSTITUTION: Melted materials are introduced into the die of a tablet stamping machine by a transport member which can be heated and next pressed and cooled in a generally used method. Still plastic and viscous materials with high temperature can also be directly measured and supplied to the die of the tablet stamping machine by a nozzle and a measuring means. Afterward, the press forming is made together with cooling in a generally used method. Just after pushing out, still hot and plastic or viscous materials are pressed and formed into solid type tablets of medical forming substance at 25 deg.C. The medical mixture to be pushed out are mixtures of one kind or plural kinds of pharmaceutics effective substances and one kind or plural kinds of supplementary agent generally used for medical tablets manufacturing.  These are one kind or plural kinds of polymer components, become a paste or viscous state by melting or softening, therefore, is possible to be pushed out.
The project will be last for 3 years. We will start to screen the patients within the community to identify the CKD population. This population will randomized into two group (one group with standard nephrologist care and another group with standard nephrologist care plus multidisciplinary CKD education) to evaluate the effectiveness of CKD education on the progression of renal function. The primary end-point will be the doubling tine estimated GFR, development of end-stage renal disease and all cause mortality. The non-CKD group of community will also follow up for urine and blood test for renal function, to determine the incidence and risk factors of new-onset renal disease. The accomplishment of this study will retard renal progression, improve community health and establish a model in preventing the chronic kidney disease.
An N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, a preparation method and an application. The structure of the compound is represented by formula (I). The compound can generate a rapid and reversible general anesthesia effect. Animal experiments show that the compound has rapid and short-acting pharmacological characteristics and can be used as a rapid and short-acting general anesthesia medicine. Meanwhile, compared with etomidate, the compound can reduce the inhibition on synthesis of adrenal cortical hormone, recovery is rapid and thorough, and the compound has obvious advantages and good application prospects. The only chiral carbon in the structure of the compound must be of R type. The imidazole ring in the structure of the compound has acidifiable N atoms, so that the compound and medicinal salt molecules thereof can be applied to the preparation of central inhibitory medicines capable of generating sedative, hypnotic and/or anesthetic effects on animals or human through veins or paths outside veins.
Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
The interactions between vascular cells, especially endothelial cells, and macrophages play a pivotal role in maintaining the subtle balance of vascular biology, which is crucial for angiogenesis in both healthy and diseased states. These cells are central to ensuring a harmonious balance between tissue repair and preventing excessive angiogenic activity, which could lead to pathological conditions. Recent advances in sophisticated genetic engineering vivo models and novel sequencing approaches, such as single-cell RNA-sequencing, in immunobiology have significantly enhanced our understanding of the gene expression and behavior of macrophages. These insights offer new perspectives on the role macrophages play not only in development but also across various health conditions. In this review, we explore the complex interactions between multiple types of macrophages and endothelium, focusing on their impact on new blood vessel formation. By understanding these intricate interactions, we aim to provide insights into new methods for managing angiogenesis in various diseases, thereby offering hope for the development of novel therapeutic approaches.
Patients randomized to the test arm will undergo radiotherapy to the residual mass. Patients will be stratified by the size of the residual mass in shortest dimension being \<3 cm or \> 3 cm.A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
PURPOSE:To obtain a skin cosmetic effective to the promotion of the health and beauty of the skin and the protection of the skin, by compounding two or more sugars selected from specific sugars such as glucose, fructose, sucrose, 1-kestose, nistose, etc., to the aqueous base of a skin cosmetic. CONSTITUTION:Two or more sugars selected from glucose, fructose, sucrose, 1-kestose, nistose, and 1F-fructofuranosylnistose are added to an aqueous base of a water-based skin cosmetic, e.g. lotions such as face lotion, emulsified cosmetic such as cream, milky lotion, etc., transparent gelatinous cosmetic such as film-type skin pack, etc. in an amount of 0.01-30wt%, preferably 0.1-20wt% based on the whole components. A skin cosmetic prepared by this process has excellent stability with time, gives excellent feeling, gloss and springiness to the skin, and has excellent physiological effects to the skin, e.g. effect to improve the chapped skin, moisturizing effect, effect to improve the roughened skin, etc.
PROBLEM TO BE SOLVED: To provide a moisturizing gel sheet made from natural materials alone, good at the function of retaining its shape and having moderate mechanical strength. SOLUTION: This moisturizing gel sheet is obtained by binding the slimy component (poly-γ-glutamic acid) of Natto (fermented soybeans) as a natural material to a substrate (e.g. nonwoven fabric, cotton, paper); specifically, this moisturizing gel sheet is produced by the following process: a diepoxy compound is added to a 2-15% poly-γ-glutamic acid aqueous solution followed by agitation, the resultant solution is applied onto the substrate followed by drying and concurrently carrying out crosslinking reaction. This moisturizing gel sheet thus obtained is infiltrated with a lotion or refreshing agent to be used as a face mask or cooling sheet or the like. In the above gel sheet, the diepoxy compound to be used is such one as to be nonirritant to the skin, being e.g. ethylene glycol diglycidyl ether.  This moisturizing gel sheet has moderate mechanical strength, swelling only in the thickness direction, and being good at the function of retaining its shape in the longitudinal and transverse planar direction.
Self-administration of 70 mg etripamil for a perceived episode of PSVT followed 10 minutes later by an optional second dose of 70 mg etripamil, if symptoms persisted. Participants could be enrolled in the open-label period to treat an additional PSVT episode with etripamil.
BACKGROUND: Women with complex health needs are more at risk of having children's social care involvement with their newborns than other mothers. Around the time of pregnancy, there are opportunities for health services to support women with these needs and mitigate the risk of mother-baby separation. Yet little is known about healthcare professionals' experiences of providing this support.
METHODS: We administered an online survey to perinatal healthcare professionals across England (n=70 responders), including midwives, obstetricians, perinatal psychologists/psychiatrists and health visitors. We asked about their experiences of providing care for pregnant women with chronic physical conditions, mental health needs, intellectual/developmental disabilities and substance use disorders, who might be at risk of children's social care involvement. We conducted a framework analysis.
RESULTS: We constructed five themes from participant data. These include (1) inaccessible healthcare for women with complex needs, (2) the challenges and importance of restoring trust, (3) services focusing on individuals, not families, (4) the necessity and caution around multidisciplinary support and (5) underfunded services inhibiting good practice.
CONCLUSIONS: Women who are at risk of children's social care involvement will likely experience perinatal healthcare inequities. Our findings suggest that current perinatal healthcare provision for this population is inadequate and national guidelines need updated to inform support.
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of COZAAR.

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen (BUN) or serum creatinine were observed in less than 0.1 percent of patients with essential hypertension treated with COZAAR alone (see PRECAUTIONS, Impaired Renal Function).

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.11 grams percent and 0.09 volume percent, respectively) occurred frequently in patients treated with COZAAR alone, but were rarely of clinical importance. No patients were discontinued due to anemia.

Liver Function Tests: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. In patients with essential hypertension treated with COZAAR alone, one patient (<0.1%) was discontinued due to these laboratory adverse experiences.
GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
Atherosclerotic cardiovascular disease is the cause for over 19 million deaths in the US annually with coronary artery disease accounting for most of this mortality burden.1 Despite major advances in the treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. For those who arrive alive at an emergency department, a benefit is accrued from an orchestrated program of live-saving therapeutics designed to preserve ischemic or infarcted myocardium and prevent ventricular arrhythmias. However, despite improvements in door-to-balloon (angioplasty) times in the past decade, reductions in in-hospital mortality have not materialized.2 Average 30-day mortality from ST elevation MI has been shown to be approximately 7% despite the modern aggressive approach of utilizing acute pharmacologic and percutaneous interventions as well as a comprehensive approach to risk factor modification.3 Antiplatelet agents including aspirin, clopidogrel, heparin, and IIb/IIIa inhibitors represent stalwart components of the acute coronary syndrome therapeutic treatment program. At the same time, the safety of combination antiplatelet agents used acutely and chronically in individuals with an acute coronary syndrome is concerning as bleeding complications can result in serious, life-threatening consequences.4 Studies have shown that patients treated with the combination of aspirin and clopidogrel have a small but significant increased risk of major and minor bleeding compared to each agent alone.4-6 In contrast, the use of fish oil in conjunction with aspirin and clopidogrel in patients with cardiovascular disease followed for an average of 33 months has been shown to have no significant effect on risk of major and minor bleeding compared to those on aspirin and clopidogrel alone, with a trend toward a reduced risk of minor bleeding in those taking fish oil.4 In Preliminary Data it is shown that a robust synergistic effect between Lovaza® and aspirin on the downregulation of platelet function may occur. These data suggest that the most potent omega-3 fatty acids found in fish oil (eicosapentaenoic acid {EPA} and docosahexaenoic acid {DHA}) act acutely to modulate a major contributor to the pathophysiology of acute coronary syndromes. This study will randomize 60 patients with ST elevation myocardial infarction to treatment with Lovaza® or placebo and measure the differences in platelet function and electrophysiologic parameters between treatment arms during their acute hospitalization and 1 week after discharge.
Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
The slow absorption rate of this preparation may allow once-daily administration in adult non-smokers with appropriate total body clearance and other patients with low dosage requirements. Once-daily dosing should be considered only after the patient has been gradually and satisfactorily titrated to therapeutic levels with q12h dosing. Once-daily dosing should be based on twice the q12h dose and should be initiated at the end of the last q12h dosing interval. The trough concentration (Cmin) obtained following conversion to once-daily dosing may be lower (especially in high clearance patients) and the peak concentration (Cmax) may be higher (especially in low clearance patients) than that obtained with q12h dosing. If symptoms recur, or signs of toxicity appear during the once-daily dosing interval, dosing on the q12h basis should be reinstituted.

It is essential that serum theophylline concentrations be monitored before and after transfer to once-daily dosing.

Food and posture, along with changes associated with circadian rhythm, may influence the rate of absorption and/or clearance rates of theophylline from extended-release dosage forms administered at night. The exact relationship of these and other factors to nighttime serum concentrations and the clinical significance of such findings require additional study. Therefore, it is not recommended that theophylline extended-release once-daily dosing be administered at night.
A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
Optimising the cardiac output is essential to ensure adequate organ perfusion in patients who are undergoing major surgery. To enable this cardiac output (CO) is frequently monitored during operations using a variety of techniques; one such technique is trans-oesophageal Doppler ultrasound also known as oesophageal Doppler monitoring (ODM). ODM measurement of CO is a less invasive technique than many currently used methods, and has recently been recommended by NICE for adoption in clinical practice. The matching of microvascular blood flow and CO is advantageous for visceral organs, in marrying demands for oxygen and nutrients to their delivery. Major surgery and the attendant requirement for general anaesthesia can result in dramatic changes in blood pressure (BP) and CO. These changes can be corrected by the administration of vasoactive drugs such as phenylephrine and ephedrine, although it is unclear what effects these drugs have on microvascular blood flow (MVBF) to the intra-abdominal viscera. Whilst they correct falls in BP, and hence may increase visceral flow, this increased BP is partially mediated via splanchnic vasoconstriction, which may result in decreased blood flow. A greater appreciation of the effect of these vasoactive drugs on the CO and MVBF may help with the development of more refined algorithms for their use in the clinical setting. In our clinical physiology laboratories we regularly employ contrast-enhanced ultrasound (CEUS) using a Phillips iU22, to measure MVBF in healthy males following a variety of physiological challenges. This minimally invasive ultrasound based imaging technique is ideal for gaining an insight into the effect various physiological interventions have on tissue blood flow and could be readily used to chart changes in visceral MVBF and CO following vasoactive drug administration. Transference of this investigative approach to a clinical setting has the potential to greatly improve the care of the surgical patient under anaesthesia.
The increasing frequency of zoonotic spillover events and viral mutations in low and middle-income countries presents a critical global health challenge. Contributing factors encompass cultural practices like bushmeat consumption, wildlife trade for traditional medicine, habitat disruption, and the encroachment of impoverished settlements onto natural habitats. The existing "vaccine gap" in many developing countries exacerbates the situation by allowing unchecked viral replication and the emergence of novel mutant viruses. Despite global health policies addressing the root causes of zoonotic disease emergence, there is a significant absence of concrete prevention-oriented initiatives, posing a potential risk to vulnerable populations. This article is targeted at policymakers, public health professionals, researchers, and global health stakeholders, particularly those engaged in zoonotic disease prevention and control in low and middle-income countries. The article underscores the importance of assessing potential zoonotic diseases at the animal-human interface and comprehending historical factors contributing to spillover events. To bridge policy gaps, comprehensive strategies are proposed that include education, collaborations, specialized task forces, environmental sampling, and the establishment of integrated diagnostic laboratories. These strategies advocate simplicity and unity, breaking down barriers, and placing humanity at the forefront of addressing global health challenges. Such a strategic and mental shift is crucial for constructing a more resilient and equitable world in the face of emerging zoonotic threats.
Those assigned to the accelerated bilateral sequential theta burst stimulation (absTBS)-sham arm shall receive the blinded active absTBS treatment at Week 1. At Week 3, they shall receive the blinded sham treatment.
Abstract of the Disclosure A bonding agent composition for use in dental restorations for bonding porcelain to the metal core or framework, especially framework of non-precious metal alloys.  The bonding agent composition comprises: (a) a bond-forming component comprising a powdered mixture of aluminum and a glass which fuses at a temperature in the range of from about 1750°F to about 1850°F and (b) ? liquid carrier.  The carrier is preferably one capable of  ?  viding a reducing atmosphere at temperatures within the range of from about 1200°F to about 1900°F.  The bonding agent composition is applied to a metal core which is to be faced with porcelain and heated from about 1200°F. to a temperature in the range of about 1750°F. to 1900°F. to produce a very strong bond at the interface resistant to separation of the porcelain by stresses placed upon the restoration during use.